Ansuman Satpathy, a newly appointed director of 10x Genomics, Inc., filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 6, 2026, disclosing no securities beneficially owned as of the event date of October 28, 2026.

Key Highlights

  • Reporting person: Ansuman Satpathy filed as a director of 10x Genomics, Inc. (NASDAQ:TXG).
  • Event date: The date of event requiring the statement was October 28, 2026.
  • No securities held: According to the filing, "No securities are beneficially owned."
  • No derivative securities: Table II disclosed no derivative securities, including no options, warrants, or convertible securities.
  • Signed by attorney-in-fact: The form was signed by Randy Wu as attorney-in-fact for Ansuman Satpathy on November 6, 2026.

Ansuman Satpathy Joins 10x Genomics Board With No Initial Securities Position

Ansuman Satpathy filed an Initial Statement of Beneficial Ownership, the form required when a person first becomes subject to Section 16(a) reporting obligations, in connection with his role as a director of 10x Genomics, Inc. The filing covers the period beginning October 28, 2026, which the form identifies as the date of the event requiring the statement.

Both Table I, covering non-derivative securities, and Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, were left blank. The filing states explicitly that "No securities are beneficially owned," meaning Satpathy reported neither direct nor indirect ownership of any class of 10x Genomics securities as of the event date. No explanation of responses or additional remarks were included beyond the reference to Exhibit 24.1, a Power of Attorney.

The form was filed individually, as a single reporting person, and was executed by Randy Wu acting as attorney-in-fact for Ansuman Satpathy. The filing was submitted to the SEC on November 6, 2026, and relates to 10x Genomics, Inc., listed on NASDAQ under the symbol TXG, with principal offices noted at 6230 Stoneridge Mall Road, Pleasanton, California 94588.

What Was Disclosed

Ansuman Satpathy filed an initial beneficial ownership statement as a new director of 10x Genomics, Inc., reporting no ownership of any non-derivative or derivative securities of the company as of October 28, 2026.